The Global Pemetrexed
Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was
valued at US$ 2,062.5 Mn in 2017, and is projected to exhibit a CAGR of 1.3%
during the forecast period (2018–2026).
Approval and launch of affordable
generic of Pemetrexed in the market, which is expected to increase its adoption
and drive global pemetrexed market growth. Alimta is a patented drug of Eli
Lilly and Company, it has vitamin regimen patent in the U.S. and Europe up to
2021 and pediatric exclusivity in the U.S. up to 2022. However, patent for
compound of Alimta expired in the U.S. in January 2017, and expired in major
European countries and Japan in December 2015. Hence, key players in the market
have developed and gained approval for generic versions of Alimta in key
regions. For instance, in 2017, Eagle Pharmaceuticals Inc. received the U.S.
Food and Drug Administration (FDA) approval for its diluted version of Eli
Lilly and Co’s blockbuster cancer drug Alimta. Launch of generic versions of
Pemetrexed is expected to increase the affordability of drugs as generic drugs
are cost effective.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2458
However, it is projected to
affect the revenues to Eli Lilly and Company’s branded drug over the forecast
period. Eli Lilly and Company is dedicated to expand the indication of Alimta
(Pemetrexed), such expansion of indication is expected to support global
Pemetrexed market growth. For instance, in 2012, Alimta received the FDA
approval, as maintenance therapy for locally advanced or metastatic NSCLC,
following initial ALIMTA-plus-cisplatin treatment for locally advanced or
metastatic nonsquamous NSCLC. In 2018, ALIMTA received FDA approval for an
additional indication for the combination with carboplatin plus pembrolizumab
as first-line treatment for metastatic nonsquamous NSCLC, irrespective of PD-L1
expression status
Browse 18 Market Data Tables and
20 Figures spread through 130 Pages and in-depth TOC on Global Pemetrexed
Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies), and Region (North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa) -
Alimta is a patented drug of Eli
Lilly and Company, hence Eli Lilly and Company is delicately working to prevent
the launch of generic version of Alimta in key region such as U.S. from where
Alimta generates about 50% of its revenue. For instance, in June 2018, Eli
Lilly and Company got a favorable result from U.S. District Court and prevented
Hospira Inc. and India’s Dr. Reddy’s Laboratories from launching generic
version of Alimta until the patent expires in 2022.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/pemetrexed-market-2458
Key Takeaways of the Pemetrexed
Market:
The global Pemetrexed market is
expected to exhibit a CAGR of 1.3% during the forecast period (2018 – 2026),
owing approval and launch of affordable generic of pemetrexed in the market,
which is expected to increase its adoption.
North America is expected to
account for major market share in global pemetrexed market, owing to high
prevalence of non-small cell lung cancer and its high treatment rate.
Launch of generic version of
Pemetrexed in Germany by STADAPHARM GmbH in July 2018, is expected to increase
the affordability of drug in region. However, it will affect the revenue of Eli
Lilly and Company branded drug Alimta
Eli Lilly and Company, the patent
holder of Alimta is dedicated to prevent the launch of generic version of
Alimta in key regions to hold major share in market.
Major players operating in the
global Pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG,
Eagle Pharmaceuticals, Inc., and Others
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2458
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment